Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | MASP2 | O00187 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548417 | 1.00 | CTSK (0.58) | CTSKCTSSSYKATMSIGMAR1 | |
| SCHEMBL3604545 | 0.86 | MMP2 (0.58) | CTSKCTSSSYKATMIDO1 | |
| SCHEMBL2548981 | 0.86 | MMP2 (0.58) | CTSKCTSSSYKATMIDO1 | |
| SCHEMBL2548977 | 0.86 | MMP2 (0.58) | CTSKCTSSSYKATMIDO1 | |
| SCHEMBL8239858 | 0.85 | CTSK (0.56) | CTSKCTSSSYKATMSIGMAR1 | |
| SCHEMBL23699285 | 0.84 | CTSK (0.55) | CTSKCTSSSYKATMSIGMAR1 | |
| SCHEMBL23699373 | 0.82 | SYK (0.54) | CTSKCTSSSYKATMSIGMAR1 | |
| SCHEMBL18085403 | 0.80 | CTSK (0.54) | CTSKCTSSSYKATMSIGMAR1 | |
| SCHEMBL8175909 | 0.80 | SYK (0.48) | CTSKCTSSSYKATM | |
| SCHEMBL4343821 | 0.79 | MMP2 (0.51) | MASP2F2ANPEPERAP1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287561-A1 | Inhibitors of AKT Activity | NOVARTIS AG (CH) | 2016-10-06 | — | — | US | disclosed |
| US-20150152092-A1 | INHIBITORS OF Akt ACTIVITY | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-8946278-B2 | Inhibitors of AkT activity | GLAXOSMITHKLINE LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | GLAXOSMITHKLINE LLC (US) | 2013-09-05 | — | — | US | disclosed |
| CN-101646427-B | Inhibitors of akt activity | SMITHKLINE BEECHAM CORP US | 2013-06-12 | — | — | CN | disclosed |
| US-8410158-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410158-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2188282-B1 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-8273782-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273782-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110071182-A1 | Inhibitors of AKT Activity | SMITHKLINE BEECHAM CORPORATION | 2011-03-24 | — | — | US | disclosed |
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| CN-101646427-A | Inhibitors of akt activity | SMITHKLINE BEECHAM CORP US | 2010-02-10 | — | — | CN | disclosed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| WO-2008098104-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2007076423-A2 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | CTSK 1012/4885CTSS 1420/4885SYK 599/4885 |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | AKT2, AKT1, AKT3 | CTSK 1012/4885CTSS 1420/4885SYK 599/4885 |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | CTSK 1012/4885CTSS 1420/4885SYK 599/4885 |
| US-20160287561-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | CTSK 1012/4885CTSS 1420/4885SYK 599/4885 |
| US-20110071182-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | CTSK 1012/4885CTSS 1420/4885SYK 599/4885 |
| US-20150152092-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | CTSK 1012/4885CTSS 1420/4885SYK 599/4885 |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | CTSK 1012/4885CTSS 1420/4885SYK 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.